Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Myomo Reports Second Quarter 2026 Financial and Operating Results
Myomo reported Q2 2026 revenue of $11.7 million, up 21% year-over-year, driven by higher volume and pricing with 211 MyoPro units recognized.
Gross margin expanded 940 basis points to 72.1% while operating expenses remained flat, narrowing the operating loss to $2.3 million and improving Adjusted EBITDA by 79%.
Management raised full-year 2026 revenue guidance to $45-47 million, supported by expanded payer access and growing clinical referrals.